This was indeed important to determine, because in the only frail 53-year-old patient, CD38-based induction and ASCT had been the TB-recommendation, whereas CD38-based therapy alone would have been the better TB-choice according to the R-MCI assessment. The gene discussed is CD38; the disease is tuberculosis.